MannKind (NASDAQ: MNKD) — Company Overview, News & Financial Data
MannKind develops innovative therapeutic products, including inhalable insulin for diabetes management.
MannKind
MannKind (NASDAQ:MNKD) is dedicated to discovering, developing, and commercializing innovative therapeutic products for patients with diseases such as diabetes. Central to its portfolio is Afrezza, an inhalable insulin offering a unique administration method compared to traditional insulin delivery mechanisms, aimed at improving the quality of life for those managing their diabetes. Beyond diabetes, MannKind is exploring opportunities to leverage its technosphere technology platform to create inhalable therapeutic products for other conditions. Their objective is to expand the application of their technology to address unmet medical needs across various diseases, pushing the boundaries of what's possible in medical science and improving patient outcomes.
Snapshot
Operations
Products and/or services of MannKind
- Afrezza, an inhalable insulin for adults with diabetes, offers a rapid-acting mealtime blood sugar control alternative.
- Technosphere technology, a versatile pulmonary drug delivery platform designed to improve medication efficacy and patient compliance.
- Tyvaso DPI, developed in collaboration with United Therapeutics for pulmonary arterial hypertension, leverages Technosphere for targeted delivery.
- Epalrestat inhalation powder, an investigational treatment for diabetic peripheral neuropathy, aiming to reduce symptoms and progression.
- Collaboration with Vertice Pharma to create inhalable treatments for orphan lung diseases, expanding therapeutic options for rare conditions.
- MannKind is exploring inhaled therapeutic options for oncology, aiming to develop innovative treatments for cancer patients.
MannKind executive team
- Michael E. CastagnaCEO & Director
- Christopher B. PrentissChief Financial Officer
- David B. ThomsonExecutive VP, General Counsel & Secretary
- Stuart A. TrossChief People & Workplace Officer
- Dominic MarascoPresident of Endocrine Business Unit
- Sanjay SinghExecutive Vice President of Technical Operations
- Ajay AhujaExecutive VP & Chief Medical Officer
- Wassim FaresSenior VP and Therapeutic Area Head of Respiratory & (interim) Cariorenal
Latest news about MannKind
MannKind signs GLP-1 inhalation deal
United StatesMannKind wins FDA approval for 80 mg Furoscix
United StatesMannKind hits dual trial milestones for inhaled lung fibrosis drug
United StatesMannKind eyes pediatric market with INHALE-1ST trial and upcoming FDA verdict
United StatesMannKind gains FDA nod for Afrezza dosing guide
United States
Key financials
Reported results for MannKind , in USD.
- Market cap
- 1.1B
- Revenue (TTM)
- 393.6M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- -11.1%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 349M | 38.8M | 5.9M | |
| 285.5M | 72.6M | 27.6M | |
| 199M | 8.7M | -11.9M | |
| 99.8M | -64.1M | -87.4M |